Opinion|Videos|August 15, 2024
TRANSCEND CLL 004 Data Review and its Impact on Future Treatment Practices
Key opinion leaders analyze the implications of the FDA's accelerated approval for lisocabtagene maraleucel (liso-cel) in chronic lymphocytic leukemia, based on promising results from the TRANSCEND CLL 004 trial.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly comment on the recent FDA accelerated approval granted to lisocabtagene maraleucel (liso-cel) based on the findings from TRANSCEND CLL 004.
- How may this impact future treatment practices? In which patients may you consider this treatment approach?
Advertisement
Related to this article
Lisaftoclax plus acalabrutinib earned breakthrough therapy status in China for untreated CLL/SLL.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
The top 5 OncLive TV videos of the week.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Full Approval to Pembrolizumab for Unresectable/Metastatic TMB-H Solid Tumors
2
HER2+ mCRC Treatment Sequencing Favors Tucatinib Plus Trastuzumab Before T-DXd
3
Polls Reveal Top Picks for Lung Cancer Abstracts of Interest at ESMO 2026
4
Poll Results Highlight Gynecologic Cancer Abstracts of Interest at ESMO 2026
5